Effects of Intracoronary Nicorandil on Myocardial Microcirculation and Clinical Outcomes in Patients with Acute Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials

No abstract is available for this paper.

• Publication year

  2019

• Venue

  American Journal of Cardiovascular Drugs

• Publication date

  2019-08-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40256-019-00368-yPMID 31423544
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nicorandil

  2024cited by this paper
• Effects of Early Intracoronary Administration of Nicorandil During Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction.

  2019cited by this paper
• Intracoronary Nicorandil and the Prevention of the No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction

  2018cited by this paper
• Effect of nicorandil administration on myocardial microcirculation during primary percutaneous coronary intervention in patients with acute myocardial infarction

  2018cited by this paper
• Cardioprotective Effects of Nicorandil on Coronary Heart Disease Patients Undergoing Elective Percutaneous Coronary Intervention

  2017cited by this paper
• Intracoronary administration of anisodamine and nicorandil in individuals undergoing primary percutaneous coronary intervention for acute inferior myocardial infarction: A randomized factorial trial.

  2015cited by this paper
• Myocardial no-reflow treatment.

  2013cited by this paper
• Usefulness of transient and persistent no reflow to predict adverse clinical outcomes following percutaneous coronary intervention.

  2012cited by this paper
• Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction

  2011cited by this paper
• Myocardial no-reflow in humans.

  2009cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• Effect of intra-coronary nicorandil administration prior to reperfusion in acute ST segment elevation myocardial infarction.

  2008cited by this paper
• Relation of myocardial blush grade to microvascular perfusion and myocardial infarct size after primary or rescue percutaneous coronary intervention.

  2007cited by this paper
• Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART).

  2006cited by this paper
• Cochrane Handbook for Systematic Reviews of Interventions Edited by Julian P. T. Higgins &

  2006cited by this paper
• Intracoronary nicorandil prior to reperfusion in acute myocardial infarction.

  2006influential reference
• Impact of a Single Intravenous Administration of Nicorandil Before Reperfusion in Patients With ST-Segment–Elevation Myocardial Infarction

  2005cited by this paper
• Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction.

  2005cited by this paper
• Comparison between nicorandil and magnesium as an adjunct cardioprotective agent to percutaneous coronary intervention in acute anterior myocardial infarction.

  2004cited by this paper
• Nicorandil versus isosorbide dinitrate as adjunctive treatment to direct balloon angioplasty in acute myocardial infarction

  2004cited by this paper
• Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial.

  2002cited by this paper
• No-reflow phenomenon.

  2002cited by this paper
• The “no-reflow” phenomenon: basic science and clinical correlates

  2002cited by this paper
• Interrater Reliability of the Modified Jadad Quality Scale for Systematic Reviews of Alzheimer’s Disease Drug Trials

  2001cited by this paper
• TIMI frame count immediately after primary coronary angioplasty as a predictor of functional recovery in patients with TIMI 3 reperfused acute myocardial infarction.

  2001cited by this paper
• Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction.

  2000cited by this paper
• Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs.

  2000cited by this paper
• ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators.

  2000cited by this paper
• Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease.

  2000cited by this paper
• Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction.

  1999cited by this paper
• Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group.

  1998cited by this paper
• Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels.

  1995cited by this paper
• Operating characteristics of a rank correlation test for publication bias.

  1994cited by this paper
• Incidence and treatment of 'no-reflow' after percutaneous coronary intervention.

  1994cited by this paper
• Nicorandil as a hybrid between nitrates and potassium channel activators.

  1989cited by this paper

• The effect of nicorandil compared to placebo on cardiac outcomes of patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis

  2025cites this paper
• The Effect of Nicorandil on Blood Flow Perfusion in the Left Anterior Descending Artery during Off-Pump Coronary Artery Bypass Grafting

  2025cites this paper
• Intracoronary Injection of Nicorandil Alleviates No-Reflow in Elderly Patients with Acute STEMI Undergoing Emergency PCI

  2024cites this paper
• Evaluation of Nicorandil in Treatment of induced pulmonary arterial hypertension in male Rats

  2024cites this paper
• Nicorandil protects against coronary microembolization-induced myocardial injury by suppressing cardiomyocyte pyroptosis via the AMPK/TXNIP/NLRP3 signaling pathway.

  2022cites this paper
• Assessment of the Efficacy and Safety of Early Intracoronary Nicorandil Administration in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

  2022cites this paper
• Effects of Nicorandil Administration on Infarct Size in Patients With ST‐Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The CHANGE Trial

  2022cites this paper
• Mitochondrial dysfunction in cardiovascular disease: Current status of translational research/clinical and therapeutic implications

  2020cites this paper
• Effect of nicorandil treatment adjunctive to percutaneous coronary intervention in patients with acute myocardial infarction: a systematic review and meta-analysis

  2020cites this paper